読み込み中
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
終値時点
$25.04
+$0.41 · +1.66%
時間外
$25.04
$0.00 · 0.00%
10月12日 16:04 ET
日中の時刻はETです。市場データは遅延する場合があります。
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
日中レンジ
現在 $25.04
52週レンジ
現在 $25.04
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
14
著しい割高
センチメント
47
まちまち
リスク
45
やや高いリスク
モメンタム
61
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
日中レンジ
現在 $25.04
52週レンジ
現在 $25.04
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.26億 USD | 1.1億 USD | 1.75億 USD | 1.65億 USD | 2.75億 USD |
| 売上原価 | 1051.2万 USD | 2.28億 USD | — | 2億 USD | 1.93億 USD |
| 粗利益 | 1.15億 USD | −1.17億 USD | 1.75億 USD | −3498.4万 USD | 8260.4万 USD |
| 研究開発 | 2.39億 USD | 2.28億 USD | 2.54億 USD | 2億 USD | 1.93億 USD |
| 販売・一般管理 | 6364.4万 USD | 5888.6万 USD | 5337.9万 USD | 4748.9万 USD | 3883.7万 USD |
| 営業費用 | 2.93億 USD | 6121.5万 USD | 3.07億 USD | 4748.9万 USD | 3883.7万 USD |
| 受取利息 | 2752.4万 USD | 3193万 USD | 1862.6万 USD | 481.7万 USD | 86.2万 USD |
| 支払利息 | 3192.7万 USD | 3664.3万 USD | — | — | 1.3万 USD |
| 減価償却費と償却費 | 1051.2万 USD | 1210.7万 USD | 1149.8万 USD | 879.9万 USD | 749.1万 USD |
| 営業利益 | −1.78億 USD | −1.78億 USD | −1.32億 USD | −8247.3万 USD | 4376.7万 USD |
| 純利益 | −9192.3万 USD | −2.33億 USD | −1.33億 USD | −5518.1万 USD | 8263.1万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI6391.7万0.00%2.3兆 USD0.03%$381.58-0.09%
iShares Russell 2000 ETFIWM4484.4万0.06%787.4億 USD0.19%$277.88-0.38%
State Street SPDR S&P Biotech ETFXBI3162万0.32%98.74億 USD0.35%$151.39-1.55%
Vanguard Extended Market ETFVXF2342.71万0.02%954億 USD0.05%$233.46-0.66%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1544.31万0.10%158.4億 USD0.03%$53.44-0.02%
iShares Biotechnology ETFIBB1338.32万0.12%108.2億 USD0.44%$204.26-1.08%
Invesco S&P SmallCap Momentum ETFXSMO1109.33万0.39%28.69億 USD0.35%$81.32-0.53%
Vanguard Russell 2000 ETFVTWO1091.28万0.06%180億 USD0.06%$112.27-0.35%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Biotechnology ETFIBBInvesco S&P SmallCap Momentum ETFXSMOVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
